Advertisement

Picture EBD Group BioPharm America 2019 Boston September 650x65px
Document › Details

Graffinity Pharmaceuticals GmbH. (3/30/11). "Press Release: Graffinity Enters into Drug Discovery Collaboration with Shionogi". Heidelberg.

Organisations Organisation Graffinity Pharmaceuticals GmbH (new, since 2006)
  Group Novalix (Group)
  Organisation 2 Shionogi & Co., Ltd.
  Group Shionogi (Group)
Products Product fragment-based drug discovery services
  Product 2 surface plasmon resonce technology (SPR technology)
Persons Person Woker, Mathias (AMSilk 201210– CBO located in Boston before Graffinity 200603 Senior VP BusDev US)
  Person 2 Schmidt, Kristina (Lipid Therapeutics GmbH 201205– COO before Graffinity 200601–201204 CEO + Founder)
     


Graffinity Pharmaceuticals GmbH, a member of the NovAliX group of companies (www.novalix.com), announced today that it has entered into a research collaboration with Osaka, Japan based Shionogi & Co., Ltd. Under the terms of the agreement, Graffinity will receive technology access fees and payments for follow-up chemistry for the generation of various, novel small molecule hits against a key drug target.

Financial details of the transaction were not disclosed.

Mathias Woker, Chief Business Officer of Graffinity, remarked, ”We are pleased that Shionogi has chosen to collaborate with us to apply our fragment based screening platform to one of Shionogi’s high priority discovery programs. This marks our first collaboration with a leading Japanese pharmaceutical company. Our proprietary assay/label-free SPR primary screen of 24,000 fragments and 87,000 leadlike molecules is often crucial in addressing drug targets that are difficult to screen with other technologies.”


About Graffinity Pharmaceuticals GmbH

Heidelberg, Germany based Graffinity Pharmaceuticals, a member of the NovAliX group of companies (www.novalix.com), is a leader in the field of small molecule fragment-based drug discovery. Graffinity’s fragment screening platform combines chemical microarrays with a proprietary method for the standardized, label-free detection of compound-protein interactions via SPR-imaging. The company’s rapid and scalable drug discovery technology explores a rich chemical universe to identify drug fragments which address challenging drug targets. With its 110,000-compound library that contains 24,000 true fragments, Graffinity possesses one of the most diverse fragment libraries. Graffinity’s unique fragment based discovery platform was invented in 1998, and has been in routine industrial use since 2002 in screening more than 90 drug targets.

For more information, please visit www.graffinity.com.

Graffinity Media Contact for Europe:

Dr. Kristina Schmidt
CEO
Graffinity Pharmaceuticals GmbH
Tel. +49 6221 6510-112
kristina.schmidt@graffinity.com

Graffinity Media Contact for the Americas and Asia:

Mathias Woker
CBO
Graffinity Pharmaceuticals GmbH
Tel. +1 (401) 301-1086
mathias.woker@graffinity.com

# # #

   
Record changed: 2019-06-09

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Novalix (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2019 Boston September 650x65px




» top